In vitro and ex vivo systems at the forefront of infection modeling and drug discovery

Add time:08/10/2019    Source:sciencedirect.com

Bacterial infections and antibiotic resistant bacteria have become a growing problem over the past decade. As a result, the Centers for Disease Control predict more deaths resulting from microorganisms than all cancers combined by 2050. Currently, many traditional models used to study bacterial infections fail to precisely replicate the in vivo bacterial environment. These models often fail to incorporate fluid flow, bio-mechanical cues, intercellular interactions, host-bacteria interactions, and even the simple inclusion of relevant physiological proteins in culture media. As a result of these inadequate models, there is often a poor correlation between in vitro and in vivo assays, limiting therapeutic potential. Thus, the urgency to establish in vitro and ex vivo systems to investigate the mechanisms underlying bacterial infections and to discover new-age therapeutics against bacterial infections is dire. In this review, we present an update of current in vitro and ex vivo models that are comprehensively changing the landscape of traditional microbiology assays. Further, we provide a comparative analysis of previous research on various established organ-disease models. Lastly, we provide insight on future techniques that may more accurately test new formulations to meet the growing demand of antibiotic resistant bacterial infections.

We also recommend Trading Suppliers and Manufacturers of Ex 169 (cas 132420-05-4). Pls Click Website Link as below: cas 132420-05-4 suppliers

Prev:Futures minimum variance hedge ratio determination: An ex-ante analysis
Next:The accuracy of benefit-cost analyses (BCAs) in transportation: An ex-post evaluation of road projects)